While the FDA acknowledged reports of adverse reactions from semaglutide, an active ingredient of Ozempic, the regulator did not specifically cite Ozempic or its manufacturer, Novo Nordisk, as the cause of these reports.
Drug Safety-related Labeling Changes (SrLC)